Immune checkpoint inhibitors, such as anti-PD-1 (e.g., pembrolizumab) and anti-CTLA-4 (e.g., ipilimumab) antibodies, have revolutionized cancer treatment by reactivating antitumor immunity and are now being explored in sepsis to reverse immune paralysis and restore immune function. The gene discussed is CTLA4; the disease is cancer.